An improved isoprenylcysteine carboxylmethyltransferase inhibitor induces cancer cell death and attenuates tumor growth in vivo

Cancer Biology and Therapy

Volumn 15, Issue 9, 2014, Pages 1280-1291

  Lau, Hiu Yeung ^a   Ramanujulu, Pondy M ^b   Guo, Dianyan ^a   Yang, Tianming ^b   Wirawan, Melissa ^a   Casey, Patrick J ^a   Go, Mei Lin ^b   Wang, Mei ^a  

^a DUKE NUS MEDICAL SCHOOL   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Anti proliferation; Autophagy; Compound 8.12; Cysmethynil; Gefitinib; Icmt; Ras; Synergy

Indexed keywords

ANTINEOPLASTIC AGENT; CYSMETHYNIL; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; INDOLE DERIVATIVE; LAMIN A; PROTEIN METHYLTRANSFERASE; PROTEIN P21; PROTEIN-S-ISOPRENYLCYSTEINE O-METHYLTRANSFERASE; PYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE;

ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; AUTOPHAGY; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; DRUG POTENTIATION; FEMALE; HUMAN; LIVER NEOPLASMS; METABOLISM; METHYLATION; PATHOLOGY; PROTEIN PRENYLATION; SCID MOUSE; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOPHAGY; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG SYNERGISM; FEMALE; HETEROGRAFTS; HUMANS; INDOLES; LAMIN TYPE A; LIVER NEOPLASMS; METHYLATION; MICE, SCID; ONCOGENE PROTEIN P21(RAS); PROTEIN METHYLTRANSFERASES; PROTEIN PRENYLATION; PYRIMIDINES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84906829065     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.29692     Document Type: Article

References (47)

1. Berndt N, Hamilton AD, Sebti SM. Targeting protein prenylation for cancer therapy. Nat Rev Cancer 2011; 11:775-91; PMID:22020205; http://dx.doi.org/10. 1038/nrc3151
2. Gao J, Liao J, Yang GY. CAAX-box protein, prenylation process and carcinogenesis. Am J Transl Res 2009; 1:312-25; PMID:19956441
3. Ahearn IM, Haigis K, Bar-Sagi D, Philips MR. Regulating the regulator: post-translational modification of RAS. Nat Rev Mol Cell Biol 2012; 13:39-51; PMID:22189424; http://dx.doi.org/10.1038/nrm3255
4. Casey PJ, Seabra MC. Protein prenyltransferases. J Biol Chem 1996; 271:5289-92; PMID:8621375; http://dx.doi.org/10.1074/jbc.271.10.5289
5. Otto JC, Kim E, Young SG, Casey PJ. Cloning and characterization of a mammalian prenyl protein-specific protease. J Biol Chem 1999; 274:8379-82; PMID:10085068; http://dx.doi.org/10.1074/jbc.274.13.8379
6. Dai Q, Choy E, Chiu V, Romano J, Slivka SR, Steitz SA, Michaelis S, Philips MR. Mammalian prenylcysteine carboxyl methyltransferase is in the endoplasmic reticulum. J Biol Chem 1998; 273:15030-4; PMID:9614111; http://dx.doi.org/10.1074/jbc.273.24.15030
7. Wright LP, Court H, Mor A, Ahearn IM, Casey PJ, Philips MR. Topology of mammalian isoprenylcysteine carboxyl methyltransferase determined in live cells with a fluorescent probe. Mol Cell Biol 2009; 29:1826-33; PMID:19158273; http://dx.doi.org/10.1128/MCB.01719-08
8. Yang J, Kulkarni K, Manolaridis I, Zhang Z, Dodd RB, Mas-Droux C, Barford D. Mechanism of isoprenylcysteine carboxyl methylation from the crystal structure of the integral membrane methyltransferase ICMT. Mol Cell 2011; 44:997-1004; PMID:22195972; http://dx.doi.org/10.1016/j.molcel.2011.10.020
9. Bergo MO, Leung GK, Ambroziak P, Otto JC, Casey PJ, Gomes AQ, Seabra MC, Young SG. Isoprenylcysteine carboxyl methyltransferase deficiency in mice. J Biol Chem 2001; 276:5841-5; PMID:11121396; http://dx.doi.org/10.1074/jbc. C000831200
10. Bergo MO, Gavino BJ, Hong C, Beigneux AP, McMahon M, Casey PJ, Young SG. Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf. J Clin Invest 2004; 113:539-50; PMID:14966563; http://dx.doi.org/10.1172/ JCI200418829
11. Wahlstrom AM, Cutts BA, Liu M, Lindskog A, Karlsson C, Sjogren AK, Andersson KM, Young SG, Bergo MO. Inactivating Icmt ameliorates K-RAS-induced myeloproliferative disease. Blood 2008; 112:1357-65; PMID:18502828; http://dx.doi.org/10.1182/blood-2007-06-094060
12. Baines AT, Xu D, Der CJ. Inhibition of Ras for cancer treatment: the search continues. Future Med Chem 2011; 3:1787-808; PMID:22004085; http://dx.doi.org/10.4155/fmc.11.121
13. Slebos RJ, Hoppin JA, Tolbert PE, Holly EA, Brock JW, Zhang RH, Bracci PM, Foley J, Stockton P, McGregor LM, et al. K-ras and p53 in pancreatic cancer: association with medical history, histopathology, and environmental exposures in a population-based study. Cancer Epidemiol Biomarkers Prev 2000; 9:1223-32; PMID:11097231
14. John J, Sohmen R, Feuerstein J, Linke R, Wittinghofer A, Goody RS. Kinetics of interaction of nucleotides with nucleotide-free H-ras p21. Biochemistry 1990; 29:6058-65; PMID:2200519; http://dx.doi.org/10.1021/ bi00477a025
15. Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 2013; 503:548-51; PMID:24256730; http://dx.doi.org/10.1038/nature12796
16. James GL, Goldstein JL, Brown MS. Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. J Biol Chem 1995; 270:6221-6; PMID:7890759; http://dx.doi.org/10.1074/jbc.270.11.6221
17. Whyte DB, Kirschmeier P, Hockenberry TN, Nunez-Oliva I, James L, Catino JJ, Bishop WR, Pai JK. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 1997; 272:14459-64; PMID:9162087; http://dx.doi.org/10.1074/jbc.272.22.14459
18. Winter-Vann AM, Baron RA, Wong W, dela Cruz J, York JD, Gooden DM, Bergo MO, Young SG, Toone EJ, Casey PJ. A small-molecule inhibitor of isoprenylcysteine carboxyl methyltransferase with antitumor activity in cancer cells. Proc Natl Acad Sci U S A 2005; 102:4336-41; PMID:15784746; http://dx.doi.org/10.1073/pnas.0408107102
19. Wang M, Tan W, Zhou J, Leow J, Go M, Lee HS, Casey PJ. A small molecule inhibitor of isoprenylcysteine carboxymethyltransferase induces autophagic cell death in PC3 prostate cancer cells. J Biol Chem 2008; 283:18678-84; PMID:18434300; http://dx.doi.org/10.1074/jbc.M801855200
20. Cushman I, Casey PJ. Role of isoprenylcysteine carboxylmethyltransferase- catalyzed methylation in Rho function and migration. J Biol Chem 2009; 284:27964-73; PMID:19651782; http://dx.doi.org/10.1074/jbc.M109.025296
21. Cushman I, Casey PJ. RHO methylation matters: a role for isoprenylcysteine carboxylmethyltransferase in cell migration and adhesion. Cell Adh Migr 2011; 5:11-5; PMID:20798596; http://dx.doi.org/10.4161/cam.5.1.13196
22. Go ML, Leow JL, Gorla SK, Schüller AP, Wang M, Casey PJ. Amino derivatives of indole as potent inhibitors of isoprenylcysteine carboxyl methyltransferase. J Med Chem 2010; 53:6838-50; PMID:20809634; http://dx.doi.org/10.1021/jm1002843
23. Ramanujulu PM, Yang T, Yap SQ, Wong FC, Casey PJ, Wang M, Go ML. Functionalized indoleamines as potent, drug-like inhibitors of isoprenylcysteine carboxyl methyltransferase (Icmt). Eur J Med Chem 2013; 63:378-86; PMID:23514631; http://dx.doi.org/10.1016/j.ejmech.2013.02.007
24. Bergo MO, Leung GK, Ambroziak P, Otto JC, Casey PJ, Young SG. Targeted inactivation of the isoprenylcysteine carboxyl methyltransferase gene causes mislocalization of K-Ras in mammalian cells. J Biol Chem 2000; 275:17605-10; PMID:10747846; http://dx.doi.org/10.1074/jbc.C000079200
25. Davies BS, Fong LG, Yang SH, Coffinier C, Young SG. The posttranslational processing of prelamin A and disease. Annu Rev Genomics Hum Genet 2009; 10:153-74; PMID:19453251; http://dx.doi.org/10.1146/annurev-genom-082908-150150
26. Ibrahim MX, Sayin VI, Akula MK, Liu M, Fong LG, Young SG, Bergo MO. Targeting isoprenylcysteine methylation ameliorates disease in a mouse model of progeria. Science 2013; 340:1330-3; PMID:23686339; http://dx.doi.org/10.1126/ science.1238880
27. Wang M, Hossain MS, Tan W, Coolman B, Zhou J, Liu S, Casey PJ. Inhibition of isoprenylcysteine carboxylmethyltransferase induces autophagic-dependent apoptosis and impairs tumor growth. Oncogene 2010; 29:4959-70; PMID:20622895; http://dx.doi.org/10.1038/onc.2010.247
28. Zhu WL, Hossain MS, Guo DY, Liu S, Tong H, Khakpoor A, Casey PJ, Wang M. A role for Rac3 GTPase in the regulation of autophagy. J Biol Chem 2011; 286:35291-8; PMID:21852230; http://dx.doi.org/10.1074/jbc.M111.280990
29. Kimura S, Noda T, Yoshimori T. Dissection of the autophagosome maturation process by a novel reporter protein, tandem fluorescent-tagged LC3. Autophagy 2007; 3:452-60; PMID:17534139
30. Yang YP, Liang ZQ, Gu ZL, Qin ZH. Molecular mechanism and regulation of autophagy. Acta Pharmacol Sin 2005; 26:1421-34; PMID:16297339; http://dx.doi.org/10.1111/j.1745-7254.2005.00235.x
31. Wang M, Khoo YM, Zhou J, Casey P, Lee HS. A high-performance liquid chromatography method for the quantification of cysmethynil, an inhibitor of isoprenylcysteine carboxylmethyl transferase, in mouse plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877:553-7; PMID:19157999; http://dx.doi.org/10.1016/j.jchromb.2008.12.067
32. Kobayashi K, Hagiwara K. Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC). Target Oncol 2013; 8:27-33; PMID:23361373; http://dx.doi.org/10.1007/s11523-013-0258-9
33. Ono M, Hirata A, Kometani T, Miyagawa M, Ueda S, Kinoshita H, Fujii T, Kuwano M. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Mol Cancer Ther 2004; 3:465-72; PMID:15078990
34. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006; 58:621-81; PMID:16968952; http://dx.doi.org/10.1124/pr.58.3.10
35. Han W, Pan H, Chen Y, Sun J, Wang Y, Li J, Ge W, Feng L, Lin X, Wang X, et al. EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells. PLoS One 2011; 6:e18691; PMID:21655094; http://dx.doi.org/10.1371/journal.pone.0018691
36. Cheng Y, Zhang Y, Zhang L, Ren X, Huber-Keener KJ, Liu X, Zhou L, Liao J, Keihack H, Yan L, et al. MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis. Mol Cancer Ther 2012; 11:154-64; PMID:22057914; http://dx.doi.org/10.1158/1535-7163.MCT-11-0606
37. Dragowska WH, Weppler SA, Wang JC, Wong LY, Kapanen AI, Rawji JS, Warburton C, Qadir MA, Donohue E, Roberge M, et al. Induction of autophagy is an early response to gefitinib and a potential therapeutic target in breast cancer. PLoS One 2013; 8:e76503; PMID:24146879; http://dx.doi.org/10.1371/ journal.pone.0076503
38. Al-Lazikani B, Banerji U, Workman P. Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol 2012; 30:679-92; PMID:22781697; http://dx.doi.org/10.1038/nbt.2284
39. Delbaldo C, Michiels S, Syz N, Soria JC, Le Chevalier T, Pignon JP. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA 2004; 292:470-84; PMID:15280345; http://dx.doi.org/10.1001/jama.292.4.470
40. Zimmermann GR, Lehár J, Keith CT. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today 2007; 12:34-42; PMID:17198971; http://dx.doi.org/10.1016/j.drudis.2006.11.008
41. Sakuma Y, Matsukuma S, Nakamura Y, Yoshihara M, Koizume S, Sekiguchi H, Saito H, Nakayama H, Kameda Y, Yokose T, et al. Enhanced autophagy is required for survival in EGFR-independent EGFR-mutant lung adenocarcinoma cells. Lab Invest 2013; 93:1137-46; PMID:23938604; http://dx.doi.org/10.1038/labinvest. 2013.102
42. Zhai B, Hu F, Jiang X, Xu J, Zhao D, Liu B, Pan S, Dong X, Tan G, Wei Z, et al. Inhibition of akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma. Mol Cancer Ther 2014; 13:1589-98; PMID:24705351; http://dx.doi.org/ 10.1158/1535-7163.MCT-13-1043
43. Court H, Amoyel M, Hackman M, Lee KE, Xu R, Miller G, Bar-Sagi D, Bach EA, Bergö MO, Philips MR. Isoprenylcysteine carboxylmethyltransferase deficiency exacerbates KRAS-driven pancreatic neoplasia via Notch suppression. J Clin Invest 2013; 123:4681-94; PMID:24216479; http://dx.doi.org/10.1172/ JCI65764
44. Hamer PJ, Trimpe KL, Pullano T, Ng S, LaVecchio JA, Petit DA, DeLellis R, Wolfe H, Carney WP. Production and characterization of anti-RAS p21 monoclonal antibodies. Hybridoma 1990; 9:573-87; PMID:2076896; http://dx.doi.org/10.1089/ hyb.1990.9.573
45. Ragnauth CD, Warren DT, Liu Y, McNair R, Tajsic T, Fig. N, Shroff R, Skepper J, Shanahan CM. Prelamin A acts to accelerate smooth muscle cell senescence and is a novel biomarker of human vascular aging. Circulation 2010; 121:2200-10; PMID:20458013; http://dx.doi.org/10.1161/CIRCULATIONAHA.109.902056
46. Shiwarski DJ, Dagda RK, Chu CT. Red and Green Puncta Colocalization Macro. 2014
47. Pampliega O, Orhon I, Patel B, Sridhar S, Díaz-Carretero A, Beau I, Codogno P, Satir BH, Satir P, Cuervo AM. Functional interaction between autophagy and ciliogenesis. Nature 2013; 502:194-200; PMID:24089209; http://dx.doi.org/10.1038/nature12639